While current supplies of these novel medications are limited due to production bottlenecks (Lipanovic, 2024), one might expect a decrease in patient out-of-pocket costs due to expansion of production capacity (Novo Nordisk, 2024), increased market competition (Liu et al., 2021, Collins et al., 2024), expanded insurance coverage (Liu and Rome, 2024, Cubanski and Neuman, 2024), and, eventually, expiration of patent protections (Alhiary et al., 2023)
doi:10.1016/j.regpep.2004.07.009 68 RowlandKJBrubakerPL
NMDA blockers have been shown to induce weight loss in preclinical models, but when delivered systemically, these drugs have significant side effects, such as an increase in body temperature and hyperactivity
As other drug manufacturers join the GLP-1 race, Gan & Lee Pharmaceuticals in Beijing, China, is developing a novel biweekly GLP-1 for weight loss
Higher doses do not necessarily produce better results and may increase the risk of side effects like headaches or gastrointestinal discomfort without improving fat loss outcomes